Navigation Links
Patients, Doctors, Pharmacists Praise Bipartisan House Resolution on Compounded Hormones Containing Estriol
Date:5/7/2008

MISSOURI CITY, Texas, May 7 /PRNewswire-USNewswire/ - The International Academy of Compounding Pharmacists today joined hundreds of thousands of women and doctors in applauding the introduction of H. Con. Res. 342, a bipartisan resolution stating that "the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest" and calling on the FDA to "reverse its policy."

Reps. Mike Ross (D-Ark.), Jo Ann Emerson (R-Mo.), Sam Farr (D-Calif.), Tammy Baldwin (D-Wisc.), Michael Burgess (R-Texas), John Carter (R-Texas) and Gabrielle Giffords (D-Ariz.) introduced the resolution in the House of Representatives.

"We commend all of the sponsors for standing up for women and introducing H. Con. Res. 342," said L.D. King. "Women with menopause suffer enough. Fortunately, this resolution aims to provide them with some relief."

For decades, doctors have prescribed compounded hormones containing estriol to women suffering from the painful symptoms of menopause. IACP estimates that hundreds of thousands of women are prescribed these drugs today. FDA's policy would force these women to discontinue the hormone treatments that their doctors have determined is appropriate for them.

Wyeth petitioned the FDA in October 2005 to prohibit compounding pharmacists from preparing hormones that contain estriol on the grounds that doing so posed a "serious threat to public health." At the same time, though, Wyeth was marketing drugs containing estriol as "an ideal therapy" across Europe.

Wyeth's petition generated more than 70,000 responses, the overwhelming majority of which from women and doctors opposed to Wyeth's request. Unfortunately, FDA fulfilled Wyeth's request earlier this year when it announced that it would "halt" the compounding of compounded hormones containing estriol.

"FDA ignored the comments of tens of thousands of women and instead listened to Wyeth," continued Mr. King. "Removing this drug from the market robs patients of a long-standing, vital and legal menopause treatment alternative to Wyeth's products. FDA's policy is an unwelcome intrusion of federal bureaucrats into thousands of doctors' offices."

Compounded hormones containing estriol are lawfully prescribed, prepared and dispensed in all 50 states and their use is accepted by the United States Pharmacopeia and the Pharmacy Compounding Accreditation Board. The FDA has acknowledged that it is unaware of any adverse events associated with the use of these drugs. Estriol is a component of a multiple sclerosis treatment undergoing Phase II clinical trials; in compounded form it is prescribed by doctors to treat both multiple sclerosis and symptoms of menopause.

Since FDA announced its estriol policy in January, the agency has since attempted to allay the concerns of thousands of women by stating that doctors may prescribe compounded hormones containing estriol if they complete an Investigational New Drug Application (IND). Unfortunately, this process is unworkable.

"FDA is trying to fit a square peg in a round hole," concluded Mr. King. "FDA is setting doctors up to fail, leaving them in the same position are they are in now -- unable to treat women with the medication of their choice."

Pharmacy compounding is a long-standing, state-regulated and medically vital practice. Millions of Americans have unique health needs that off-the-shelf prescription medications cannot meet. For them, customized, compounded medications -- prescribed or ordered by licensed physicians or veterinarians and mixed safely by trained, licensed compounding pharmacists -- are the only way to better health.

About IACP

The International Academy of Compounding Pharmacists (IACP) is a non-profit association founded in 1991 to protect and promote the art and skill of the compounding pharmacy profession. We represent more than 2,000 pharmacists, physicians, technicians and patients who are committed to the safe practice of pharmacy compounding. We are committed to ensuring the rights of physicians to prescribe, of pharmacists to prepare and of patients to take customized medications that meet their unique, individual needs.


'/>"/>
SOURCE The International Academy of Compounding Pharmacists(IACP)
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. New York City Cancer Patients, Survivors and Care Givers Encouraged to Keep Going(R)
2. Cancer patients, spouses report similar emotional distress, U-M study finds
3. Cancer patients, spouses report similar emotional distress, U-M study finds
4. Cancer Doctors Across America Stunned at Governments Ruling Restricting Anemia Management Protocols for Cancer Patients, Call Ruling Interference in Practice of Medicine
5. Sedgwick CMS Gift Supports Walter Reed Patients, Families
6. Patients, dentists differ on smile ratings, JADA study
7. For hospital patients, defibrillation delays mean lower survival
8. Interactive Teleconference on Inflammatory Bowel Disease for Patients, Caregivers, and Healthcare Professionals
9. Doctors uncertain about approaches to care for heart failure patients, SLU study finds
10. Forecasting MDs prescriptions choice? Ask their patients, says Management Insights study
11. More Than 1,000 Childrens Memorial Hospital Patients, Physicians, Elected Officials, Donors and Staff Gather to Break Ground on the Ann & Robert H. Lurie Childrens Hospital of Chicago
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... New York, New York (PRWEB) , ... May 24, 2017 , ... ... and general vascular surgery in New York City. He is known for ... his broad specialization in vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular ...
(Date:5/24/2017)... ... 2017 , ... Dr. Manju R. Kejriwal, a leading Ohio dentist, is now ... a referral. Dr. Kejriwal understands the emotional and financial toll traditional orthodontics can take ... Patients no longer need to feel the esthetic effects of wires and brackets when ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... II of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a ... advancements in his field by attending numerous CE courses each year. His recent ...
(Date:5/24/2017)... ... 24, 2017 , ... If you are thinking of a visit to San Francisco , ... is the perfect time to visit. , Business Architecture Associates is pleased to offer 5 ... individuals, as a 4-½ day package for individuals, and as 4-½ day corporate package for ...
(Date:5/24/2017)... Falls, Wisconsin (PRWEB) , ... May 24, 2017 ... ... leader in clean label food ingredient solutions for the food and beverage industry ... factor in food ingredient statements during the purchasing decision process. As a result, ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/6/2017)... 5, 2017   Provista , a proven leader in ... customers, today announced Jim Cunniff as the company,s ... and business experience to Provista, including most recently serving as ... California . He assumed his new role with ... great fit for Provista," says Jody Hatcher , president, ...
(Date:5/4/2017)... 2017  A recent study published in the ... light as a means of disinfection anesthesia workstations ... bioburden on anesthesia workstations. In the study, UVC ... medical equipment surfaces contaminated with three (3) organisms ... study further validates the body of literature supporting ...
Breaking Medicine Technology: